-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 21, Zhejiang Medicine announced that it had recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for nanoxacin malate sodium chloride injection 250ml:0.
Nenoxacin is a new type of non-fluoroquinolone antibiotic, used to treat Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae and Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella pneumophila caused mild to moderate adult (≥18 years) community-acquired pneumonia
It is understood that up to now, Zhejiang Pharmaceutical has invested about 7 million yuan in research and development expenses for the development of nanofloxacin malate sodium chloride injection project (not including the technology transfer fee of Taiwan Taijing)